# To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

> **NCT04675931** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 254 (actual)

## Conditions studied

- Severe Malaria

## Interventions

- **DRUG:** Cipargamin
- **DRUG:** IV Artesunate
- **DRUG:** Coartem

## Key facts

- **NCT ID:** NCT04675931
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-07
- **Primary completion:** 2025-07-24
- **Final completion:** 2025-08-20
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04675931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04675931, "To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04675931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*